Stay updated with breaking news from Advanced Accelerator. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.
By Adriano Marchese Lantheus Holdings is being sued by Swiss multinational pharmaceutical Novartis for patent infringement on a generic drug to treat...
Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.
Neuroendocrine Carcinoma Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The